The Heparin Calcium Market is estimated to be valued at US$ 1,370.9 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Heparin calcium is an anticoagulant (blood thinner) drug extracted from animal tissues. It acts as an anticoagulant by inhibiting blood coagulation through a combination of prolonging thrombin time, inhibiting thrombin, disabling its interaction with factors V, VIII and fibrinogen, and increasing the activity of antithrombin III. It is mainly used to prevent blood clots from forming in blood vessels, arteries and veins during procedures such as dialysis, blood transfusions and cardiac surgery.
Market Dynamics:
The heparin calcium market is driven by increasing demand for anticoagulants and growing prevalence of coagulation disorders such as deep vein thrombosis (DVT), pulmonary embolism and atrial fibrillation. According to Centers for Disease Control and Prevention (CDC), atrial fibrillation affects over 2.7 million Americans annually. The risk of developing atrial fibrillation increases with age and the condition is more prevalent in men than women. Moreover, growing geriatric population base that is prone to chronic diseases and coagulation disorders is also expected to boost market growth during the forecast period.
SWOT Analysis
Strength: Heparin calcium market has various clinical applications such as acute coronary syndrome, atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Significant research and development activities by market players to develop new drugs are expected to drive market growth.
Weakness: Stringent regulations for the approval of heparin drugs can hamper market growth. Adverse effects associated with heparin use such as bleeding risks pose challenges.
Opportunity: Increasing prevalence of cardiovascular diseases and venous thromboembolism presents lucrative growth opportunities. Growing healthcare expenditure in emerging economies provides scope for market expansion.
Threats: Expiry of patents leads to decline in sales of branded drugs. Heavy dependence on China for raw material supply acts as a threat.
Key Takeaways
The Global Heparin Calcium Market is expected to witness high growth, exhibiting CAGR of 2.7% over the forecast period, due to increasing prevalence of cardiovascular diseases. The market size for 2022 is estimated to be US$ 1,370.9 Mn.
Regional analysis
North America dominates the global market and is projected to retain its dominance over the forecast period. This is attributed to growing prevalence of chronic diseases, rising healthcare expenditure, and presence of major players in the region. Asia Pacific exhibits the fastest growth due to large patient population, improving access to healthcare facilities, and rising healthcare expenditure in countries such as China and India.
Key players
Key players operating in the heparin calcium market include Sanofi, Pfizer Inc, Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, and Shandong Sheelian Pharmaceutical Co., Ltd. Companies are increasingly investing in research and development activities to develop innovative heparin calcium drugs.
